| Species |
Human |
| Protein Construction |
TNFRSF11A/Rank (Ile30-Pro212)_x000D_
Accession # Q9Y6Q6-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human RANKL, His Tag at 2μg/ml (100μl/well) on the plate can bind TNFRSF11A/Rank hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
46.85 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
TNFRSF11A, also known as receptor activator of NF-κB (RANK), activates several signaling pathways, such as NF-κB, JNK, ERK, p38α, and Akt/PKB. RANK/TNFRSF11A is a novel and frequent target for de novo methylation in gliomas, which affects apoptotic activity and focus formation thereby contributing to the molecular pathogenesis of gliomas. |
| Synonyms |
ODFR; Receptor activator of NF-KB; NF-KB; NFKB; CD265; TNFRSF11A; Rank; FEO; LOH18CR1; OPTB7; OSTS; PDB2; TRANCER; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
